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Abstract
Background: Intestinal inflammation in Crohn’s disease (CD) is caused by mucosal immune system reactivity to
luminal antigen and results in debilitating symptoms, reduced quality of life, impaired work productivity and
significant health care costs. Not all patients respond to conventional and biologic therapies, with chronic
inflammation ensuing. Although surgical resection may be required, disease frequently returns and surgery may not
be an option, or may be declined. Case reports suggest potential benefit after haematopoietic stem cell transplant
(HSCT) for patients with refractory CD.
The ASTIC trial asked whether HSCT could cure CD. Few patients achieved the primary endpoint of clinical
remission for 3 months, off all medication with no evidence of active disease, and there were a high number of
adverse events (AEs) and serious adverse events (SAEs), including one patient death. However, beneficial effects
were observed in some aspects of disease activity. The ASTIClite trial will investigate these potential benefits and
safety using a lower intensity regimen than ASTIC.
Methods: Ninety-nine participants will be recruited from secondary care IBD centres in the UK into a multicentre,
randomised controlled trial (RCT, ASTIClite) and an observational follow-up, and randomised to autologous HSCT
versus standard care (ratio 2:1).
The primary endpoint is treatment success at week 48, defined as mucosal healing without surgery or death.
Secondary endpoints relating to efficacy, safety and mechanistic analyses will be evaluated at week 8, 14, 24, 32, 40
and 48.
Long-term safety of the low intensity HSCT regimen forms the primary endpoint for the EBMT follow-up study and
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will be assessed annually for 4–7 years.
Discussion: ASTIClite will compare HSCTlite with standard care with respect to safety, efficacy and quality of life,
and capture outcomes allowing findings to be generalised to current clinical practice in the UK. It will also provide
significant mechanistic insights into the immunological consequences of HSCTlite and its impact on treatment
outcomes. The observational follow-up will provide information, which is currently unavailable for this population.
Trial registration: The ASTIClite RCT was registered on 31st October 2017 (ISRCTN17160440) and the EBMT follow-
up study on 19th January 2018 (ISRCTN31981313).
Keywords: Crohn’s disease, Autologous stem cell transplant, Randomised controlled trial, Observational study
Background
Intestinal inflammation in Crohn’s disease (CD) is caused
by mucosal immune system reactivity to luminal antigen
and results in debilitating symptoms, reduced quality of
life, impaired work productivity and significant health care
costs [1]. CD accounts for 27,000 hospital admissions in
the UK each year [2]. Biological medications account for
the largest element of patient costs in both secondary and
tertiary care [3] with anti-TNF therapy-related costs also
having increased over the last 2 years [2].
Although many patients respond to conventional and
biologic therapies, the National Institute for Health Re-
search (NIHR) portfolio cohort trial, Personalised
Anti-TNF Therapy in Crohn’s disease (PANTS) (UKCRN
14175 & 17,747) of 1610 CD patients commencing
anti-TNF therapy reports primary non-response at week 14
in 23·8% (95% CI 21·4–26·2) and non remission at week 54
in 63·1%, (60·3–65·8) [4]. Second line therapy with the
gut-selective integrin inhibitor vedolizumab and an anti-
body against p40 (IL-12 and IL-23), ustekinumab are ap-
proved by The National Institute for Health and Care
Excellence (NICE) for patients with CD refractory to or in-
tolerant of steroids and conventional immunomodulators.
However, in one phase III trial, vedolizumab did not
achieve its induction primary endpoint in patients previ-
ously exposed to anti-TNF [5]. In another phase III trial,
vedolizumab was not more effective than placebo at week 6
among patients with refractory CD, with remission in ap-
proximately 30% of patients by week 10 [6]. Therefore, pa-
tients with treatment refractory CD face persistent
symptoms related to disease activity in addition to the mor-
bidity associated with chronic steroid exposure. Although
surgery may be an option, this may result in a permanent
stoma and is often declined. An option for patients with re-
fractory CD is haematopoietic stem cell transplant (HSCT)
for which case reports suggest exceptional benefit [7, 8].
The ASTIC trial
Under the European Society for Blood and Marrow
Transplantation (EBMT) Autoimmune Diseases Working
Party (ADWP), a randomised controlled trial, Autologous
Stem cell Transplantation for Crohn’s Disease (ASTIC)
was designed to answer the following questions; (i) does
HSCT ‘cure’ CD and (ii) is any observed benefit derived
from the cyclophosphamide or the stem cell transplant?
[9]. For this, eligible patients underwent high dose (4 g/
m2) cyclophosphamide / G-CSF mobilisation and were
then randomised to immediate HSCT or conventional
care for 1 year. Few patients in either group achieved the
primary endpoint of clinical disease remission for 3
months, off all medication, with no evidence of active dis-
ease on imaging and endoscopy. In retrospect, this pri-
mary endpoint was more ambitious than that which had
been used in any other trial published in this disease area.
In addition, it may not be in a patient’s interest to have a
protocolled withdrawal of therapy to meet the primary
endpoint (off all therapy), given that it is known patients
can relapse after HSCT and respond to therapies to which
they were previously refractory. Finally, there were a high
number of adverse (AEs) and serious adverse events
(SAEs) that were not clinically acceptable, and one patient
death. Consequently, HSCT is rarely used for patients
with refractory CD in the UK.
However, ASTIC did demonstrate significant benefits in
endpoints that are more traditional for therapeutic trials in
this area and remain of clinical importance and relevance
to patients, such as steroid-free clinical remission, mucosal
healing and quality of life [9]. After the primary endpoint,
patients in the control arm underwent HSCT. Subsequent
analysis of the impact of HSCT in all patients in the ASTIC
program reported that 50% of patients achieved regression
of all endoscopic ulceration at 1 year. In addition, clinical
factors that predict treatment success or AEs were identi-
fied [10]. A report by the EBMT in 2018, suggested that the
retrospective analysis of HSCT for CD in multiple Euro-
pean centres, autologous HSCT appeared safe and effective
in refractory CD, but that further trials are needed [11].
Risks and benefits
The incidence of CD is increasing, particularly in young
adults who may live with their disease for many decades
[1]. Patients with refractory CD suffer impaired quality
of life and disease- or treatment-related morbidity. In
addition, refractory CD is associated with a heavy
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burden of direct health care costs including disease as-
sessment, outpatient care, inpatient care, intravenous
nutrition, surgery and medication costs [2, 3]. Biological
therapies (both licensed and in phase III trials) are of a
lower efficacy in treatment-experienced patients and
have high acquisition costs. In the absence of an effect-
ive alternative, these patients are likely to be exposed to
a sequence of expensive therapies that deliver a dimin-
ishing potential for benefit and increasing risk of harm.
The ASTIC trial [9] reported a high burden of AEs
and one death. Subsequent specialist review suggested
that the high dose cyclophosphamide used at both mo-
bilisation and conditioning may have been a factor for
many of the mobilisation-related infectious AEs [12, 13].
Research also highlighted the importance of supportive
care in reducing the incidence of SAEs [14]. Analysis of
the entire ASTIC cohort using more traditional end-
points demonstrates a significant benefit of this therapy
at 1 year. Importantly, this analysis and previous studies
have suggested that HSCT appears to restore responsive-
ness to anti-TNF therapies to which patients were previ-
ously refractory [8, 10]. Furthermore, a recent single
centre cohort study with long-term clinical and endo-
scopic follow-up showed benefit extending to 5 years. Fi-
nally, reduced intensity mobilisation and conditioning
regimens have been associated with lower morbidity in
malignant and autoimmune disease [14–17].
ASTIClite
ASTIClite is a multicentre, parallel group, randomised
controlled trial designed to evaluate the efficacy of
HSCTlite at inducing regression of intestinal ulceration in
patients with refractory CD compared with standard care.
Rationale for the study
Many specialists feel it would be inappropriate to inter-
pret the complex ASTIC clinical trial with the simple
message that HSCT is not effective for refractory CD for
the following reasons [12, 13]:
1. The primary endpoint was more ambitious than in
any other CD trial and the low frequency of
patients that achieved it suggests that the trial was
underpowered;
2. Both control and intervention group received
cyclophosphamide at the relatively high dose of 4 g/
m2 for mobilisation of peripheral blood stem cells
(PBSCs), which had significant short-term beneficial
impact on disease activity;
3. No maintenance therapy was used after HSCT in
patients with recurrent disease;
4. HSCT achieved statistically significant differences
over control for secondary endpoints including
clinical remission and endoscopic disease activity;
5. Combined uncontrolled data of all transplanted
patients shows a striking reduction in clinical and
endoscopic disease activity at 1 year [10];
6. The high dose of cyclophosphamide used increased
AEs [12, 13];
7. Reduced intensity HSCT regimens and enhanced
supportive care have reduced HSCT morbidity [14, 18].
ASTIClite will therefore assess the clinical efficacy and
long-term impact of low-dose cyclophosphamide/G-CSF
mobilisation with reduced intensity conditioning in patients
with active CD refractory to biologic therapies. Embedded
mechanistic studies will assess the timeline of response, im-
mune reconstitution after HSCT and the mechanism by
which HSCT alleviates disease and restores anti-TNF re-
sponsiveness in this previously refractory group.
Aims
The main aims of this study are to assess whether stem
cell mobilisation with low-dose cyclophosphamide (1 g/
m2) and G-CSF followed by autologous transplantation
with a reduced intensity (‘HSCTlite’) conditioning regi-
men (fludarabine 125 mg/m2, cyclophosphamide 120
mg/kg and rabbit ATG 7.5 mg/kg) is safe and effective in
inducing regression of intestinal ulceration in patients
with refractory CD, when compared with standard care.
An observational follow-up study through the EBMT
will assess the long-term benefit and safety of HSCTlite
for a minimum of a further 4–7 years after the stem cell
transplant. The follow-up will also investigate the bur-
den of disease without a transplant, although no formal
comparison between groups is planned. Patients in the
control group who undergo HSCTlite after the end of
ASTIClite will continue with annual follow up in the
follow-up study.
This multi-centre RCT has been designed to have dir-
ect clinical applicability in the management of refractory
CD in the UK following completion.
The objectives of the ASTIClite RCT are:
Primary objective
 To assess the efficacy of HSCTlite compared to
standard care at inducing regression of intestinal
ulceration in patients with refractory CD at week 48;
 To investigate the long-term benefit and safety of
HSCTlite using registry-based follow up for a mini-
mum of a further 4–7 years after the stem cell
transplant.
Secondary objectives
 To assess the impact of HSCTlite on clinical disease
activity and quality of life compared to standard care.
Safety objectives
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The safety objectives in this study will initially be
assessed as part of the embedded pilot study. The Data
Monitoring and Ethics Committee (DMEC) will assess
whether low-dose cyclophosphamide and G-CSF is a
safe and effective mobilisation regimen for patients with
refractory CD. Ongoing monitoring of toxicity of
chemotherapy using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (NCI
CTCAE) will continue throughout the trial.
Exploratory objectives
 The safety and efficacy of re-introducing anti-TNF
therapy in patients who demonstrate endoscopic dis-
ease recurrence at week 24 after HSCTlite
Mechanistic objectives
HSCT is thought to induce regression of autoimmune
diseases by altering the diversity of the T cell receptor
repertoire and generating functional renewal of regula-
tory T cells and other immunoregulatory mechanisms
that establish and maintain peripheral immune tolerance
[19]. Neither the mechanism of action nor the
time-course of response in CD is known. The mechanis-
tic objectives in this study are:
 Intestinal MRI will be performed to determine the
early impact of HSCT on mucosal disease at week 4;
 Immune profiling of peripheral blood and mucosal
biopsies will:
Characterise immune re-constitution after
HSCT, assess the impact of HSCT on disease activ-
ity and interrogate relationships between parame-
ters of immune reconstitution and disease activity;
Assess immunological events that precede
disease recurrence after HSCT;
Assess the mechanism of restoration of
responsiveness to anti-TNF therapies
Serum will be stored for future immunological studies,
including an assessment of response to vaccination after
HSCT.
Methods/design
Trial design
The study is a parallel-group, controlled trial that will
randomise eligible patients to low-dose cyclophospha-
mide and G-CSF mobilisation and reduced intensity
conditioning for HSCT versus standard care (in the ratio
2:1).
Ninety-nine patients with clinical and endoscopic CD
activity who are refractory to at least two classes of bio-
logic therapy and in whom surgery is inappropriate or
has been declined, will be recruited.
Participants will be recruited from eight NHS centres
that have tertiary referral IBD clinics and HSCT will be
carried out in centres that are either JACIE accredited
for allogeneic HSCT, or for autologous HSCT if they
have previous experience of autologous HSCT for CD
(Bart’s Health, Sheffield, Nottingham, Oxford, Cam-
bridge, Liverpool, Edinburgh and Guy’s and St Thomas’
(transplants to be carried out at King’s College Hospital
for patients recruited at Guy’s and St Thomas’)) over a
3-year period, with a 1 year follow-up for the RCT.
Participants will also be invited to consent to
long-term follow up through the EBMT Registry for up
to a further 7 years.
An incorporated internal pilot will confirm whether
the mobilisation regimen of 1 g/m2 cyclophosphamide
delivers effective stem cell harvest without a flare up of
CD activity. Ability to recruit to target will be assessed
at month 10 of recruitment with STOP/GO criteria set
at 60% of the anticipated recruitment at that time.
This protocol was written in accordance with SPIRIT [20].
Participants
Potential participants will be identified by principal in-
vestigators and co-investigators through investigator
sites or as a referral through neighbouring NHS Trusts.
The trial will be discussed at local MDT meetings and
publicised more widely through dissemination practices
including press releases, websites and in journals. Any
direct patient enquiries will be directed to their usual
IBD team to seek a clinical referral to one of the partici-
pating centres for consideration for the trial.
Once identified, the potential participant will be in-
vited to discuss the trial with the principal investigator,
or delegated individual, and if they are interested will be
invited to give their permission to be discussed with the
trial MDT regarding suitability for screening.
Eligibility, consent and randomisation
Inclusion criteria
A participant is eligible for the ASTIClite RCT if the fol-
lowing criteria are met:
1. Participant of any gender, aged between 18 and 60;
2. Participants must be willing and able to provide full
informed consent;
3. Participants should be well nourished and of healthy
weight in the opinion of the PI (typically BMI > 18.5);
4. Diagnosis of CD using colonoscopy, histology and/
or radiology;
5. Disease duration of at least 6 months;
6. Disease distribution accessible to endoscopic
assessment (jejuno-ileal, ileo-caecal, or colonic);
7. Active clinical CD activity with impaired quality of
life at any time within 3 months prior to
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randomisation into the trial, as assessed by a
gastroenterology clinician;
8. Participants will be refractory or intolerant to
azathioprine, mercaptopurine or methotrexate;
9. Participants will be refractory or intolerant to at
least two classes of biologic therapy (currently anti-
TNF therapy, vedolizumab or ustekinumab), despite
dose optimisation;
10. Participants where surgery is considered not
appropriate or has been declined;
11. Endoscopic evidence of active disease in screening
(SES CD ulceration sub-score of 2 or more in at
least one segment). SES-CD will be used as stand-
ard for patients with disease in the ileum and/or
colon. Should the disease only be proximal to the
ileum, the SES-CD will still be used to score the
relevant bowel segment;
12. Satisfactory screening assessment prior to HSCT (as
per EBMT Autoimmune Disease Working Party
(ADWP) recommendations [16]);
13. Willingness to discontinue all immunosuppressant
medication after randomisation if allocated to
HSCT arm;
14. Participants, who, in the opinion of the Trial
Management Group (TMG), are fit enough to
undergo treatment.
A participant is eligible for the EBMT follow up study
if the following criteria are met:
1. Participants must have consented to take part in
the ASTIClite RCT;
2. Participants must be willing and able to provide full
informed consent, including sharing their data with
the EBMT.
Exclusion criteria
A participant is not eligible for the ASTIClite RCT if
any of the following criteria are met:
1. Diagnosis of ulcerative colitis or indeterminate
colitis;
2. No evidence of active CD on screening endoscopic
assessment;
3. Inability to assess for endoscopic active disease due
to strictures;
4. Undrained perianal fistulae (patients with previous
perianal disease or perianal disease adequately
drained with a seton in situ are eligible);
5. Presence of undrained perianal sepsis on screening
pelvic MRI;
6. Evidence of intra-abdominal sepsis on abdominal
MRI;
7. Active or latent mycobacterial infection;
8. Prior exposure to Hepatitis B, Hepatitis C or HIV;
9. Evidence of an enteric or systemic infection;
10. Participant is currently pregnant, breastfeeding, or
planning pregnancy within the duration of the
study. Current pregnancy will be confirmed with a
pregnancy test at screening assessment;
11. Unwilling to use adequate contraception (if
appropriate) until at least 12 months after the last
dose of study drug;
12. Contraindication to the use of cyclophosphamide,
fludarabine, filgrastim or rabbit ATG;
13. Participants with significant medical co-morbidity
that precludes HSCT adjudicated by the TMG;
14. Participants with significant psychiatric co-
morbidity;
15. Significant language barriers, which are likely to
affect the participant’s understanding of the study,
or ability to complete outcome questionnaires;
16. Concurrent participation in another interventional
clinical trial;
17. Participants who are not considered medically fit
for HSCT defined by any of the following:
a. Renal: creatinine clearance < 40 ml/min
(measured or estimated);
b. Cardiac: clinical evidence of refractory
congestive heart failure, left ventricular ejection
fraction < 45% by multigated radionuclide
angiography (MUGA) or cardiac echo;
uncontrolled ventricular arrhythmia; pericardial
effusion with haemodynamic consequences as
evaluated by an experienced echo
cardiographer;
c. Hepatic: AST > two times the upper limit of
normal;
d. Concurrent neoplasms or myelodysplasia;
e. Bone marrow insufficiency defined as
neutropenia with an absolute neutrophil count
< 1 × 109/l, or thrombocytopenia with a platelet
count < 50 × 109/l, or anaemia with a
haemoglobin < 80 g/l;
f. Uncontrolled hypertension, defined as resting
systolic blood pressure > = 140 mmHg and/or
resting diastolic pressure > = 90 mmHg despite
at least 2 anti-hypertensive agents (subject to
discussion at TMG);
g. Uncontrolled acute or chronic infection with
HIV, HTLV – 1 or 2, hepatitis viruses or any
other infection the investigator or TMG
consider a contraindication to participation;
h. Other chronic disease causing significant organ
failure, including established cirrhosis with
evidence of impaired synthetic function on
biochemical testing and known respiratory
disease causing resting arterial oxygen tension <
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8 kPa or CO2 tension > 6.7 kPa. FEV1/FVC <
50%. Patients not known to have respiratory
disease need not have blood gas measurements.
A participant is not eligible for the EBMT follow-up
study if any of the following criteria are met:
1. Significant language barriers, which are likely to
affect the participant’s understanding of the study,
or ability to complete outcome questionnaires.
Referral and consent
Potential participants will receive an approved partici-
pant information sheet and be given the opportunity to
ask questions to the gastroenterology and haematology
specialist teams prior to giving formal consent to
participate.
All potentially eligible participants will need to sign a
consent form to allow discussion on a case-by-case basis
by a trial MDT panel for adjudication on eligibility. At
least two gastroenterologist members of the panel, and
one haematology member must agree on inclusion of
the potential participant for them to progress to give full
consent and undergo screening assessments.
If the MDT panel deem a potential participant ineligible,
they will not be consented to the study, unless specific ac-
tions are requested such as further screening investiga-
tions, which subsequently confirm eligibility. In this case,
patients will come back to the MDT for further discussion
on eligibility, once the required actions are complete.
If the MDT agree that the potential participant appears
eligible, the patient will be invited to give full written con-
sent and proceed to screening investigations. Patients will
have the opportunity to visit their local transplant centre
and receive counselling from an independent clinician.
A medically qualified individual will confirm eligibility
and provide clinical oversight for the consent process. In
addition, patients will be asked if they wish to take part
in the EBMT follow-up study.
A screening log maintained for each site will docu-
ment all potential participants screened, whether they
were recruited, and any reasons for non-recruitment
where this information is available.
Once all screening investigations have been completed,
the investigator will re-present the participant’s case with
the trial MDT, confirming whether any information
gathered during screening raises any concerns. The trial
MDT will approve participants for randomisation if
there are no concerns.
Randomisation
Once eligibility has been confirmed and baseline data re-
corded, participants will be centrally randomised to ei-
ther the HSCTlite arm or usual care, in the ratio 2:1,
using the CTRU online randomisation system (SCRAM).
The randomisation schedule will be generated by the
blinded trial statistician prior to the start of the study.
The trial statistician will generate the schedule via
SCRAM but will remain blinded to the allocation as they
will not be able to access the schedule. Randomisation
will be stratified by centre using permuted blocks of
variable size to ensure that sufficient participants are al-
located in the correct ratio each arm of the trial within
each centre. Day 0 for the group allocated to receive
usual care will be calculated as 49 days after the date of
randomisation in order to align the length of time that
both groups are within the trial, given the time taken to
go through HSCTlite.
The patient’s GP will be informed of their participation
in the study, including their trial allocation, as will their
referring gastroenterologist (if appropriate).
Interventions
HSCTlite
Those participants randomised to receive HSCTlite will
be asked to stop their current immunosuppressant medi-
cation. As mobilisation and conditioning are intensely
immunosuppressive, additional immunosuppression is
likely to be unnecessary and may pose additional risks.
Corticosteroid medication will be continued, but weaned
according to the protocol.
Participants will then commence mobilisation of periph-
eral blood stem cells (see Table 1), starting with an infu-
sion of cyclophosphamide (1 g/m2). The mobilisation
phase can be undertaken as either an inpatient or out-
patient, depending on the sites’ local procedures. Mesna,
an NIMP in this study, is given alongside cyclophospha-
mide to prevent haemorrhagic cystitis. Four days after
cyclophosphamide infusion, participants will receive
G-CSF (filgrastim or biosimilar) 5 μg/kg. From day 8, full
blood and CD34+ cell counts will be monitored and once
peripheral blood CD34+ cell levels exceed 10 × 106/L, stem
cells will be harvested (minimum 2.0 × 106/kg CD34+
cells) and cryopreserved according to local protocols,
allowing for 10% wastage through quality assessment.
Approximately 2–4 weeks after stem cell harvest, pa-
tients will be admitted to hospital for conditioning (see
Table 2). IV fludarabine 25 mg/m2 is given on days − 6,
− 5, − 4, − 3 and − 2, along with cyclophosphamide 60
mg/kg/day on days − 3 and − 2. Rabbit ATG (2.5 mg/kg)
will be given on days − 3, − 2 and − 1. Methylpredniso-
lone will be given alongside ATG, and then tapered ac-
cording to local practice to cover ATG-related febrile
and other reactions and protect against adrenal insuffi-
ciency. As with mobilisation, Mesna will be given along-
side conditioning cyclophosphamide.
Stem cells will be reinfused on day 0, and G-CSF (fil-
grastim or biosimilar, 5 μg/kg/day) will start on day + 5
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until the absolute neutrophil counts reach > 1.0 × 109/L
for 2 consecutive days.
Supportive care will follow local standard procedures at
each centre and is at the discretion of the transplant phys-
ician, but should not include additional immunosuppression.
All transplants must be reported by the transplant cen-
tres to the EBMT database, as per standard practice. This
will include any transplants that are received outside of
the trial, while the EBMT follow-up study is in progress.
Standard care
Patients who are randomised to the standard of care
arm will continue on conventional, biologic or nutri-
tional therapy for their Crohn’s disease until assessment
of the primary endpoint. There is no restriction on the
treatment and supportive care that they can receive,
which will be dictated by either the trial site or their
regular clinical team dependent on preference. They will
undergo the study related procedures and sample collec-
tion as detailed later in the protocol.
Study procedures, sample collection and analysis
The study assessment schedule (Appendix) details the
assessments required during the study. All participants
will undergo these assessments at screening, baseline,
week 8, week 14, week 24, week 32, week 40 week 48 re-
gardless of the treatment arm to which they are rando-
mised. Participants receiving the stem cell transplant
will also have an MRI at week 4 to assess early response.
A window of +/− 1 week is permitted for each study visit
to take place. Concomitant medications and AEs will be
recorded at all study visits.
Screening and baseline assessments
Screening and baseline assessments will be performed
after informed consent and can take place over several
weeks. Screening and baseline assessments include:
1. Standard pre-HSCT workup, including chest X-ray
and cardiac echo or MUGA scan (as per EBMT
ADWP guidelines);
2. Assessment of clinical disease activity (CDAI and HBI);
3. Assessment of quality of life using patient
completed questionnaires (IBDQ, IBD-Control,
EQ5D, WPAI & Healthcare resource utilisation);
4. Endoscopic assessment of disease (endoscopic
disease activity scored using SES CD) via
colonoscopy, ileoscopy or balloon enteroscopy
depending on location;
5. MRI small bowel to record disease activity (MaRIA
score);
6. MRI pelvis in patients with previous perianal
disease to exclude perianal sepsis;
7. Confirmation of eligibility by MDT;
8. Discussion about the impact of HSCT on fertility
and referral to a fertility centre for semen or oocyte
preservation if appropriate
9. Criteria for fitness for HSCT. Participants who
meet one of more of these exclusion criteria, but in
Table 1 Timing of administration of IMP during mobilisation phase
Day 1 2 3 4 5 6 7 8 9 10 11 12
Cyclophosphamide 1 g/m2 ✓
G-CSF (filgrastim) 5 μg/kg ✓ ✓ ✓ ✓ ✓
Mesna (dose as per local practice) ✓
PB CD34 count ✓ ✓ ✓ ✓ ✓
Stem cell harvest ✓a ✓a ✓a ✓a ✓a
aStem cell harvest is approximate, the day of this will depend on adequate CD34+ counts, as described above
Table 2 Timing of administration of IMP during conditioning phase
Day −6 −5 −4 −3 −2 −1 0 1 2 3 4 5
Fludarabine 25 mg/m2/day ✓ ✓ ✓ ✓ ✓
Cyclophosphamide 60mg/kg/day ✓ ✓
Mesna (dose as per local practice) ✓ ✓
Standard hydration (as per local practice) ✓ ✓
Rabbit ATG (Thymoglobulin; Genzyme) (2.5
mg/kg/day)
✓ ✓ ✓
Methylprednisolone (1 mg/kg/day) ✓ ✓ ✓
Stem cell reinfusion ✓
G-CSF (filgrastim) (5 μg/kg/day) ✓ (continued until absolute neutrophil count > 1.0 × 109/L
for 2 days)
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the opinion of the PI are medically fit enough to
undergo HSCT, may be put forward to MDT for
discussion about eligibility.
Assessment of disease activity (MaRIA score, SES CD
and CDAI), and screening blood tests should occur within
8 weeks of randomisation. The patient will also be asked
to complete a symptom diary for a week prior to assess-
ment of the CDAI; this cannot be taken immediately pre-
ceding a colonoscopy and patients should finish the diary
prior to starting bowel prep for colonoscopy.
Procedures for assessing efficacy
Blood samples
In addition to locally processed standard blood tests,
serum and whole blood (from which will be isolated per-
ipheral blood mononuclear cells, PBMCs) will be collected
from each participant at baseline, week 8, 14, 24, 32, 40
and 48 study visits.
Routine blood tests will be analysed in local laborator-
ies. Samples for mechanistic studies will be shipped
overnight to the John van Geest Cancer Research Centre
at Nottingham Trent University, Nottingham for pro-
cessing and analysis. All sample processing, analysis and
reporting will be undertaken according to Good Clinical
Laboratory Practice (GCLP) standards.
Ileo-colonoscopy
Ileo-colonoscopy will be performed at baseline, 24 and
48 weeks, according to local practice using a standard
bowel preparation and conscious sedation. If the patient
has a stoma, endoscopy through the stoma will be per-
formed. Likewise, enteroscopy may be performed if the
disease is limited to the small intestine.
Intestinal biopsies will be taken during the endoscopy/
colonoscopy. Biopsies for routine histology will be sent
to local laboratories in formalin. Biopsies for mechanistic
analysis will be placed into RNAse reagent overnight
and stored on site at − 80 °C. Samples will be sent to the
John van Geest Cancer Research Centre every 3 months.
Videos of withdrawal from all endoscopies will be re-
corded. Eligibility for trial inclusion at baseline and the re-
quirement for anti-TNF therapy at week 24 in the
intervention group will be based upon local PI assessment
of endoscopic assessment using SES CD. In patients where
disease is proximal to the ileum, the SES CD will still be
used to score the diseased bowel segment present. All vid-
eos will be centrally read using the SES CD by investigators
blinded to site, treatment allocation and timing of proced-
ure for analysis of primary and secondary outcomes.
Stool and stem cell samples for future research
Participants will also provide stool samples, which will
be collected, frozen and stored for future studies.
Most transplant centres retain a small portion of stem
cells harvested from a patient for quality purposes. Where
possible, and with the participant’s consent, a small sample
of these stem cells will be stored and shipped to the John
van Geest Cancer Research Centre along with the other
samples, for use in future ethically-approved research.
MRI scan
MRI scans will be undertaken at baseline, 24 and 48
weeks, according to standard clinical protocols using, at a
minimum, a 1.5 T scanner and gadolinium contrast. Par-
ticipants in the intervention group will also undergo an
MRI scan at week 4, as part of the mechanistic analysis, to
determine the early impact of the intervention on mucosal
disease. Assessment for eligibility and recommencement
of anti-TNF therapy at week 24 will be performed locally.
However, sequences will also be recorded to a CD and the
validated MaRIA score will be scored centrally by an in-
vestigator who is blind to the timing of assessment and
treatment assignation, to confirm consistency.
Procedures for assessing safety
The DMEC will assess safety of the HSCTlite mobilisation
regimen after the first 10 patients, and subsequently at
each DMEC meeting. Should the protocol fail to mobilise
2 × 106 CD34+ cells/kg (haematopoietic stem and progeni-
tor cells) in more than 10% patients, or if greater than
10% patients experience a disease flare up (increase in
Harvey Bradshaw Index of > 30% from baseline associated
with a rise in CRP) during mobilisation, a protocol
amendment will be submitted to modify the mobilisation
regimen for subsequent patients.
All AEs will be recorded in the CRF and will use the
NCI classification of toxicity for 100-day safety post
HSCT for assessment of grade.
All AEs, SAEs and Suspected Unexpected Serious Ad-
verse Reactions (SUSARs) will be captured. All SAEs and
SUSARs will be reported in accordance with the CTRU’s
standard operating procedure. The Summary of Product
Characteristics (SmPCs) for relevant products will be used
as the reference safety information for reporting SAEs,
and the PI is responsible for ensuring the assessment of
expectedness and relatedness for all SAEs. Adverse events
will be recorded from consent until the study closes. Al-
though the timeframes for reporting SAEs differ between
the RCT and the follow-up study, AEs will continue to be
recorded throughout both elements of the study.
Trial outcomes
Primary outcome
The primary outcome is treatment success at week 48, de-
fined as mucosal healing (no endoscopic ulceration (SES CD
ulcer sub score = 0, assessed by central readers blind to allo-
cation and time of assessment)) without surgery or death.
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Patients who do not complete the week 48 endoscopic
assessment will be categorised as treatment failures.
The primary endpoint for the EBMT follow-up is the
long-term safety of the HSCTlite regimen, for 4–7 years
after the main ASTIClite RCT, as assessed by documenta-
tion of AEs.
Secondary outcomes
Clinical endpoints
1. Clinical remission (CDAI < 150);
2. Steroid free clinical remission (CDAI < 150);
3. Clinical remission (Harvey Bradshaw Index ≤4);
4. Clinical remission (PRO2 – mean scores –
abdominal pain ≤1, stool frequency ≤ 1.5);
5. Absolute CDAI at week 48;
6. Absolute SES CD at week 48;
7. Change in CDAI and SES CD between baseline and
week 48;
8. Proportion of patients in complete endoscopic
remission (SES CD score of 0);
9. Absolute MaRIA score at week 48.
Safety endpoints
1. Toxicity of chemotherapy using NCI CTCAE
criteria version 4.03;
2. AEs and SAEs, including mortality.
Patient-reported endpoints
1. Disease specific quality of life using the IBDQ;
2. Disease specific quality of life using the IBD
Control
3. Quality of life using the EQ-5D-5 L;
4. Health care resource utilisation questionnaire.
Exploratory secondary endpoints
1. Efficacy of re-introduction of anti-TNF therapy in
patients with disease recurrence post-HSCT
(change in CDAI at 6 weeks and change in SES CD
at 22 weeks after initiation);
2. Safety of re-introduction of anti-TNF therapy in pa-
tients with disease recurrence post-HSCT;
3. Presence of any of the late side-effects of HSCT,
documented through AEs.
Secondary outcomes for EBMT follow-up study
The secondary endpoints for this study, for 4–7 years after
stem cell transplant (and equivalent for the control arm) are:
1. Long term efficacy - for those receiving HSCT only;
2. Documentation of disease activity;
3. Requirement for further medical or surgical
intervention;
4. Disease specific quality of life using the IBDQ
questionnaire;
5. Disease specific quality of life using the IBD
Control questionnaires;
6. Quality of life using the EQ-5D-5 L questionnaire;
7. Health care resource utilisation questionnaire.
Sample size
The values in the calculations are based upon the endo-
scopic assessment post-HSCT reported in the ASTIC trial
program [9, 10]. For the primary outcome, to detect a sig-
nificant difference in the proportion of patients with ab-
sence of ulceration on endoscopic assessment of 35%,
based on 50% in the HSCT group and no more than 15%
in the control group, with 90% power at 5% significance
level requires 62 patients in the HSCT group, and 31 in
the control group. Therefore, 93 patients will be recruited
at baseline, using 2:1 randomisation. Due to the nature of
the condition, the design of the intervention and control
group, the definition of the primary endpoint and our ex-
perience in the ASTIC trial, we anticipate a 6% drop out
rate and will therefore recruit 99 patients (66 in the inter-
vention group and 33 in the control group).
Based on experience in ASTIC, recruitment is anticipated
to take 36months. Patients will be recruited at 8 UK NHS
Trusts, at an anticipated rate of 2.75 per month across all
sites, or approximately 4 patients per site per year.
For the EBMT observational follow-up study, no add-
itional sample size calculation has been performed; the
study size is necessarily constrained by the number of pa-
tients recruited within the main RCT. However, allowing for
drop-out, an expected sample size of n = 50 for the interven-
tion arm at 4 years post-transplant will allow the prevalence
of AEs to be estimated to a standard error of at most 7%.
Data collection and management
The Sheffield CTRU’s bespoke database (Prospect) will be
used to collect all trial data for the ASTIClite RCT. Site
staff have access levels granted based on their study role,
and evidence of appropriate training. Access is controlled
by individual usernames and encrypted passwords. Site
staff will enter data from source documents into Prospect,
and electronic validation rules built into the system will
ensure data queries are identified and resolved in a timely
manner, on an ongoing basis.
Questionnaires are completed by participants onto
paper copies and entered onto Prospect by site staff.
Data will be stored and managed in accordance with
CTRU Standard Operating Procedures (SOPs).
For the EBMT follow-up, the EBMT Registry database
system MACRO (Elsevier) will be used for the capture
and storage of participant data. This is a GDPR compliant
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web-based system, and access is controlled by usernames
and encrypted passwords.
Participant confidentiality will always be respected; par-
ticipants are identified only by study ID number alongside
their data. Names and addresses/email addresses are only
recorded for participants who consent to receive informa-
tion about the trial.
AEs will be collected at each participant study visit. SAEs
will be reported to the CTRU within 24 h of discovery, un-
less this is one of the exempt events defined in the protocol.
 Admissions to control symptoms of vomiting and
diarrhoea, unless the condition requires admission
to a high dependency or intensive care facility, is
life-threatening or proves fatal (i.e. grade 4 or above,
according to NCI CTCAE criteria);
 Admissions for supportive treatment during an
episode of febrile neutropenia, unless this proves
fatal or requires admission to a high dependency or
intensive care facility (i.e. grade 4 or above,
according to NCI CTCAE criteria);
 Admissions relating to myelosuppression unless the
condition requires admission to a high dependency or
intensive care facility, is life-threatening or proves fatal
(i.e. grade 4 or above, according to NCI CTCAE criteria);
 Admissions relating to skin reactions and abnormal
liver function tests caused by supportive care
medications, unless the condition requires admission
to a high dependency or intensive care facility, is
life-threatening or proves fatal (i.e. grade 4 or above,
according to NCI CTCAE criteria).
The Sheffield CTRU will be responsible for coordinating
reporting to the Sponsor, REC and MHRA as required.
Statistical analysis
ASTIClite RCT
Analyses will be reported in line with the Consolidated
Standards of Reporting Trials (CONSORT) 2010 State-
ment. Detailed descriptions of statistical analyses can be
found in the ASTIClite statistical analysis plan. The trial
statistician(s) will remain blinded throughout the study, but
will be unblinded at database freeze, for analysis. The Se-
nior Statistician within the CTRU will be unblinded to the
treatment allocation throughout the trial, but will review
and approve the statistical analysis plan before seeing any
outcome data. Confidence intervals will be two-sided, 95%
intervals and hypothesis tests will use a two-sided 5% level
of significance. The primary analyses will be carried out
using the intention to treat principle with data from all par-
ticipants included in the analysis, including those who do
not complete therapy and with participants analysed by the
group to which they were randomised. Although the trial
may terminate early on futility or safety grounds, no formal
stopping rules are defined.
Analysis will be conducted in Stata version 14 or other val-
idated statistical software as agreed by the study statisticians.
Descriptive statistics for baseline values will be presented
within each randomised group. These will include counts
and percentages for binary and categorical variables and
means and standard deviations, or medians with lower and
upper quartiles, for continuous variables, along with mini-
mum and maximum values and counts of missing values.
There will be no tests of statistical significance or confidence
intervals for differences between randomised groups on any
baseline variable. Descriptive statistics will be used to sum-
marise assessments of feasibility and acceptability in terms of
recruitment, drop-out and completeness of therapy.
To test the primary hypothesis of a between group dif-
ference in the proportion of patients with absence of ul-
ceration, we will estimate the proportions for each group.
A mixed effects logistic regression will be used to estimate
odds ratios for the disease remission in HSCTlite in com-
parison to conventional therapy. Baseline SES-CD ulcer
subscore will be included as a fixed effect and study centre
as a random effect. A number of sensitivity analyses will
be carried out on the primary outcome, including asses-
sing the impact of missing outcome data, adjustment for
baseline predictors of missing outcome data and complier
average causal effect (CACE) analysis.
For the secondary outcomes, analogous parametric re-
gression models will be used as appropriate to the distri-
butional form of the outcome, accounting for study
centre, and the corresponding baseline assessment for
the outcome under investigation where appropriate.
A secondary mediation analysis will investigate putative
mediational factors using modern causal inference
methods. This involves using parametric regression models
to test for mediation of HSCT on treatment success
through biomarkers. Analyses will adjust for baseline mea-
sures of the marker, and possible measured confounders.
Mechanistic immunology
The complex datasets will be integrated, analysed and inter-
preted using established artificial neural network (ANN) and
computational intelligence, machine-learning based approaches.
Adaptions of existing neuro-fuzzy computational intelligence
models [21] will be used to answer the questions posed. These
approaches will provide important mechanistic insight into
therapeutic responsiveness, underlying responsiveness to
anti-TNF and events that are associated with patients becom-
ing refractory to it after HSCT. Further details of the planned
mechanistic analyses have been published elsewhere [22].
Observational follow-up through the EBMT
The analysis will largely be descriptive, with incidence of
AEs, markers of disease activity, quality of life and
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resource use summarised by time point and treatment
arm. SAEs will be summarised both as the number and
percentage in each year and by the incidence per
person-year of follow-up, with the difference between
groups summarised as incidence rate ratios and 95%
confidence intervals. Continuous outcomes will be sum-
marised using means, standard deviations and medians
with interquartile ranges. Categorical variables will be
summarised as counts and percentages and compared as
the difference in percentages with 95% confidence inter-
vals. Where appropriate, multivariable analyses will be
performed using generalised linear models.
Patients who have HSCTlite after the end of the ASTI-
Clite RCT will be included in the treatment arm for the
long-term analysis for safety and efficacy. This means
that the control group may reduce in size during the
EBMT follow-up study, depending on how many pa-
tients receive transplant after the RCT.
Discussion
CD is a distressing condition, and for many patients,
there are no treatment options available to which the
disease responds. Surgery is not always an option, and
consequently some patients have a poor quality of life
and are unable to work. The ASTIC trial suggested that
HSCT could be beneficial to these patients, however,
with the trial design and dosing regimen used in ASTIC,
CD was not “cured”, and toxicity was unacceptably high
for many patients.
ASTIClite aims to achieve these suggested beneficial
outcomes, using a lower dose of the Investigational Me-
dicinal Products (IMPs) in the HSCT regimen, using pri-
mary clinical outcomes that are designed to show
beneficial effects, even if the patient still experiences CD
recurrence.
Furthermore, ASTIClite will assess the clinical efficacy
and long-term impact of lower doses of cyclophospha-
mide in the mobilisation of PBSCs followed by a reduced
intensity fludarabine, cyclophosphamide and ATG-based
conditioning regimen in patients with active CD refrac-
tory to biologic therapies. Embedded mechanistic studies
will assess the timeline of response, immune reconstitu-
tion after HSCT and the mechanism by which HSCT al-
leviates disease and/or restores anti-TNF responsiveness
in this previously refractory group.
Current status
The current protocol for the RCT is version 6.1,
05.03.2019, and for the EBMT follow up study version 3.1,
01.10.2018. The ASTIClite RCT and EBMT follow up
study both started recruiting in June 2018. Recruitment is
expected to finish in March 2021, with completion of the
RCT in March 2022, and the EBMT follow up study in
March 2026. We anticipate that results from the RCT will
be available in late 2022.
Monitoring
Conduct of the study is overseen by three committees; an
independent Trial Steering Committee (TSC) to oversee
overall trial conduct, an independent Data Monitoring
and Ethics Committee (DMEC) to monitor safety of trial
participants, and a Trial Management Group (TMG), re-
sponsible for the day-to-day running of the trial. The
TMG is made up of the site investigators, collaborators,
study management team and statisticians, and clinical
members will also discuss eligibility of all potential trial
participants, to confirm suitability for randomisation. Each
committee has a charter or terms of reference, which out-
lines the roles and responsibilities in full.
Remote monitoring will regularly review trial data,
missing data and data queries for timely resolution. In
addition, CTRU will undertake monitoring visits at each
investigator site before, during and after the trial. Cen-
tral, remote monitoring will be used alone for the obser-
vational follow-up study, after the end of the RCT.
Ethics and dissemination
The ASTIClite RCT was given a favourable ethical opin-
ion from the London – Chelsea NHS Research Ethics
Committee (reference: 17/LO/1690), and the EBMT
follow-up study from North West – Greater Manchester
East NHS Research Ethics Committee (reference: 17/
NW/1669). All protocol amendments will be approved
by the relevant ethics committee, and regulatory author-
ity as applicable, before being notified to trial
investigators.
Trial results will be disseminated in peer-reviewed sci-
entific journals and clinical and academic conferences. A
lay summary of the results will be made available on the
study website at the end of the trial and will be dissemi-
nated to participants who consented to receive informa-
tion about the trial. The main trial results will also be
published on the NIHR EME journal website.
Patient and public involvement
Patient-facing documents were reviewed by two patients
who took part in the ASTIC trial, to ensure ease of un-
derstanding, readability, format and to address any con-
cerns with the study design from a patient point of view.
Any significant amendments to patient facing docu-
ments will be discussed with this patient panel prior to
implementation.
In addition, two patient representatives are members
of the TSC, for ongoing patient involvement in the
management of the study, and a further patient per-
spective on major decisions affecting trial processes or
conduct.
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Appendix
Table 3 Study assessment schedule
Screening1 Baseline Week 4
(HSCT
only)
Week
8
Week
14
Week
24
Week
32
Week
40
Week
48
Assessments
Eligibility assessment ✓ ✓ HSCT procedure
(intervention) or
continuation on current
treatment (control)
Consent ✓
Standard Pre-HSCT work (including
chest x-ray and MUGA scan)
✓
Serology for HBV, HCV, HIV ✓
Demographics ✓
Medication history ✓
Concomitant medications ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Adverse events ✓ ✓ ✓ ✓ ✓ ✓ ✓
General Medical History ✓
History of CD ✓
General Physical Examination ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Urinalysis ✓ ✓
Pregnancy test ✓ ✓
Smoking History ✓
Crohn’s Disease Activity Index (CDAI) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Harvey Bradshaw Index ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Karnofsky Performance Status ✓ ✓
Patient Reported Outcome 2
questionnaire (PRO2)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Ileo-colonoscopy (Simple Endoscopic
Score for Crohn’s Disease (SES CD)) /
endoscopic assessment
✓ ✓ ✓
Biopsies2 ✓ ✓ ✓
MRI Intestine ✓ ✓ ✓ ✓
MRI Pelvis ✓
Routine Clinical Care blood test ✓ ✓ ✓ ✓ ✓ ✓ ✓
Serum3 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Whole Blood3 ✓ ✓ ✓ ✓ ✓ ✓
Peripheral Blood mononuclear cells
(PBMCs)3
✓ ✓ ✓ ✓ ✓ ✓
Stool sample3 ✓ ✓ ✓ ✓ ✓ ✓
Inflammatory Bowel Disease
Questionnaire (IBDQ)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Inflammatory Bowel Disease Control
Questionnaire (IBD-Control)
✓ ✓ ✓ ✓ ✓ ✓ ✓
100 day safety (collection of Adverse
Events for transplant endpoint)
✓
EQ-5D-5 L ✓ ✓ ✓ ✓ ✓ ✓ ✓
Work Productivity and Activity
Impairment questionnaire (WPAI)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Health Care Resource Use
Questionnaire
✓ ✓ ✓ ✓ ✓ ✓ ✓
Patient Global Impression of Change
(PGIC)
✓
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